Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2'-O-methylation by nsp16/nsp10 protein complex.
Chen Y, Su C, Ke M, Jin X, Xu L, Zhang Z, Wu A, Sun Y, Yang Z, Tien P, Ahola T, Liang Y, Liu X, Guo D. · 2011
Read Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2'-O-methylation by nsp16/nsp10 protein complex. by Chen Y, Su C, Ke M, Jin X, Xu L, Zhang Z, Wu A, Sun Y, Yang Z, Tien P, Ahola T, Liang Y, Liu X, Guo D. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3192843.txt.
Introduction
Yu Chen and colleagues solved the structure of a SARS virus enzyme pair that disguises viral RNA in a 2011 paper in PLoS Pathogens. Human messages wear a chemical cap, and the virus copies that cap in two steps to hide from immunity and stay stable. The second step needs two viral proteins working together, one of them only as an activator, which is unusual.
Bench tests showed the enzyme pair accepts only correctly pre-capped RNA, unlike its partner enzyme that accepts any start. The activator proved necessary for gripping both the RNA and the chemical donor. The crystal structure shows the activator propping open the donor pocket and lengthening the RNA groove. The authors propose the protein interface, rather than the enzyme's active site, as the sharper target for anti-coronavirus drugs.
Catalog record
| CREATOR | Chen Y, Su C, Ke M, Jin X, Xu L, Zhang Z, Wu A, Sun Y, Yang Z, Tien P, Ahola T, Liang Y, Liu X, Guo D. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 78 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Biochemical and Structural Insights into the Mechanisms of SARS Coronavirus RNA Ribose 2′-O-Methylation by nsp16/nsp10 Protein Complex By Yu Chen, Ceyang Su, Min Ke, Xu Jin, Lirong Xu, Zhou Zhang, Andong Wu, Ying Sun, Zhouning Yang, Po Tien, Tero Ahola, Yi Liang Published in: PLoS Pathogens DOI: 10.1371/journal.ppat.1002294 ABSTRACT The 5′-cap structure is a distinct feature of eukaryotic mRNAs, and eukaryotic viruses generally modify the 5′-end of viral RNAs to mimic cellular mRNA structure, which is important for RNA stability, protein translation and viral immune escape. SARS coronavirus (SARS-CoV) encodes two S-adenosyl-L-methionine (SAM)-dependent methyltransferases (MTase) which sequentially methylate the RNA cap at guanosine-N7 and ribose 2′-O positions, catalyzed by nsp14 N7-MTase and nsp16 2′-O-MTase, respectively. A unique feature for SARS-CoV is that nsp16 requires non-structural protein nsp10 as a stimulatory factor to execute its MTase activity. Here we report the biochemical characterization of SARS-CoV 2′-O-MTase and the crystal structure of nsp16/nsp10 complex bound with methyl donor SAM. We found that SARS-CoV nsp16 MTase methylated m7GpppA-RNA but not m7GpppG-RNA, which is in contrast with nsp14 MTase that functions in a sequence-independent manner. We demonstrated that nsp10 is required for nsp16 to bind both m7GpppA-RNA substrate and SAM cofactor. Structural analysis revealed that nsp16 possesses the canonical scaffold of MTase and associates with nsp10 at 1∶1 ratio. The structure of the nsp16/nsp10 interaction interface shows that nsp10 may stabilize the SAM-binding pocket and extend the substrate RNA-binding groove of nsp16, consistent with the findings in biochemical assays. These results suggest that nsp16/nsp10 interface may represent a better drug target than the viral MTase active site for developing highly specific anti-coronavirus drugs. INTRODUCTION Coronaviruses are etiological agents of respiratory and enteric diseases in livestock, companion animals and humans, exemplified by severe acute respiratory syndrome coronavirus (SARS-CoV) which was responsible for a worldwide SARS outbreak in 2003 and caused over 8000 cases of infection with about 10% fatality rate. They are characterized by possessing the largest and most complex positive-stranded RNA genome (ranging from 27 to 31 kb) among RNA viruses. Fourteen open reading frames (ORFs) have been identified in the genome of SARS-CoV, of which 12 are located in the 3′-one third of the genome, encoding the structural and accessory proteins translated through a nested set of subgenomic RNAs [1], [2]. The 5′-proximal two thirds of the genome comprise 2 large overlapping ORFs (1a and 1b), which encode two large replicase polyproteins that are translated directly from the genome RNA, with 1b as the frameshifted extension of 1a. These two precursor polyproteins are cleaved into 16 mature replicase proteins, named as non-structural protein (nsp) 1–16, which form the replication-transcription complex (RTC) localized in endoplasmic reticulum-derived membranes [3], [4]. Strikingly, the coronavirus genome is predicted to encode several RNA processing enzymes that are not common to small RNA viruses [1], including nsp14 as an exoribonuclease and guanine N7-methyltransferase (N7-MTase) [5], [6], [7], [8] and nsp15 as a nidovirus-specific endonuclease [9], [10]. Eukaryotic and most viral mRNAs possess a 5′-terminal cap structure, in which an N7-methyl-guanine moiety is linked to the first transcribed nucleotide by a 5′-5′ triphosphate bridge [11], [12]. The cap structure is essential for efficient splicing, nuclear export, translation and stability of eukaryotic mRNA [13], [14], [15], [16]. All viruses use the translational machinery of host cells. With the exception of some viruses, such as picornaviruses and hepatitis C virus that circumvent the capping problem by using an internal ribosome entry site (IRES) for mRNA translation [17], [18], viruses of eukaryotes have evolved diversified strategies to cap their mRNAs that are thus translated by cap-dependent mechanisms in the manner of eukaryotic mRNAs. It has been suggested for three decades that coronavirus mRNA may carry a 5′-cap structure [19], [20], [21], [22], but the principal enzymes involved in coronavirus RNA capping and their biochemical mechanisms have not been characterized until recently. Cap formation of eukaryotic and viral mRNAs requires universally three sequential enzymatic reactions. First, an RNA triphosphatase (TPase) removes the γ-phosphate group from the 5′-triphosphate end (pppN) of the nascent mRNA chain to generate the diphosphate 5′ -ppN. Subsequently, a RNA guanylyltransferase (GTase) transfers a GMP to the 5′-diphosphate end to yield the cap core structure (GpppN). Then a N7-MTase methylates the capping guanylate at the N7 position to produce a cap-0 structure (m7GpppN) [13]. While lower eukaryotes, including yeast, employ a cap-0 structure, higher eukaryotes and viruses usually further methylate the cap-0 structure at the ribose 2′-O position of the first and second nucleotide of the mRNA by a ribose 2′-O MTase to form cap-1 and cap-2 structure, respectively [13]. Very recently, it was shown that ribose 2′-O-methylation of viral RNA cap provides a mechanism for viruses to escape host immune recognition [23], [24]. For coronaviruses, several nsps have been indicated to be involved in viral RNA capping. We have shown that SARS-CoV nsp14, a previously described exoribonuclease, acts as N7-MTase to generate cap-0 structure [8]. Recently, it was shown that SARS-CoV nsp16 acts as 2′-O-MTase in complex with nsp10 and selectively 2′-O-methylates the cap-0 structure to give rise to cap-1 structure [25]. Feline coronavirus (FCoV) nsp16 was also shown to bind N7-methyl guanosine cap (m7GpppAC3-6) and methylate the penultimate nucleotide at 2′-O position to yield a cap-1 structure in vitro [26]. Coronavirus nsp13 has been shown to exhibit RNA TPase activity in vitro and thus proposed to be functional in RNA capping reaction [27], [28], but a direct role for nsp13 in RNA capping still awaits experimental evidence. Currently, the RNA GTase that is essential for cap formation is completely unknown for coronaviruses. SARS-CoV nsp16 requires nsp10 as a stimulatory factor to execute its 2′-O-MTase activity [25] and this also holds true for other coronaviruses (our unpublished results). This mechanism is unique for 2′-O-MTase of coronaviruses and has not been found in any other viruses or host cells. However, the molecular mechanisms underlying the enzymatic activity of nsp16 and the stimulatory effect of nsp10 are unknown. Here we report the crystal structure of the heterodimer of nsp16 and nsp10 (nsp16/nsp10) with bound methyl donor SAM and biochemical characterization of the stimulation mechanisms. We found that nsp10 is required for nsp16 to bind both SAM and RNA substrate, and the crystal structure shows that nsp10 may stabilize the SAM-binding pocket and extend the RNA-binding groove of nsp16. These results have implications for designing specific anti-coronavirus drugs to control infection. RESULTS Specific 2′-O-methylation of GpppA-capped RNA by SARS-CoV nsp14/nsp16/nsp10 complex In our previous work, we adopted a genetic screening system and biochemical assays to identify SARS-CoV nsp14 as N7-MTase [8]. However, we did not observe any 2′-O-MTase activity in various biochemical assays for SARS-CoV nsp16, which was previously predicted to be 2′-O-MTase [1], [29], although a low 2′-O-MTase activity was demonstrated for feline coronavirus nsp16 [26]. We and others showed previously that SARS-CoV nsp10 could interact with both nsp14 and nsp16 [30], [31], suggesting a role for nsp10 in the functions of nsp14 and nsp16. Therefore, we undertook to test the effects of nsp10 on the MTase activities of both nsp14 and nsp16. As shown in Figure 1A, by using radiolabeled and unmethylated G*pppA-capped RNA as substrate (where the * indicates that the following phosphate was 32P labeled, and the sequence is